John D. Mendlein
2017
In 2017, John D. Mendlein earned a total compensation of $3.1M as Former CEO/Current Director at aTYR PHARMA, a 99% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $165,750 |
|---|---|
| Option Awards | $2,412,378 |
| Salary | $518,167 |
| Other | $20,603 |
| Total | $3,116,898 |
Mendlein received $2.4M in option awards, accounting for 77% of the total pay in 2017.
Mendlein also received $165.8K in non-equity incentive plan, $518.2K in salary and $20.6K in other compensation.
Rankings
In 2017, John D. Mendlein's compensation ranked 3,471st out of 14,666 executives tracked by ExecPay. In other words, Mendlein earned more than 76.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,471 out of 14,666 | 76th |
Division Manufacturing | 1,198 out of 5,772 | 79th |
Major group Chemicals And Allied Products | 329 out of 2,075 | 84th |
Industry group Drugs | 251 out of 1,731 | 86th |
Industry Biological Products, Except Diagnostic Substances | 47 out of 313 | 85th |
Source: SEC filing on April 3, 2018.
Mendlein's colleagues
We found three more compensation records of executives who worked with John D. Mendlein at aTYR PHARMA in 2017.